Alpha 1-antitrypsin deficiency cost-effectiveness of therapy

Alpha 1-antitrypsin deficiency Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Alpha 1-antitrypsin deficiency from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications, and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X Ray
CT
MRI
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Alpha 1-antitrypsin deficiency cost-effectiveness of therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Alpha 1-antitrypsin deficiency cost-effectiveness of therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Alpha 1-antitrypsin deficiency cost-effectiveness of therapy
CDC on Alpha 1-antitrypsin deficiency cost-effectiveness of therapy
Alpha 1-antitrypsin deficiency cost-effectiveness of therapy in the news
Blogs on Alpha 1-antitrypsin deficiency cost-effectiveness of therapy
Directions to Hospitals Treating Alpha 1-antitrypsin deficiency
Risk calculators and risk factors for Alpha 1-antitrypsin deficiency cost-effectiveness of therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: